Movatterモバイル変換


[0]ホーム

URL:


SG11201908678XA - Methods and compositions for reduction of immunogenicity - Google Patents

Methods and compositions for reduction of immunogenicity

Info

Publication number
SG11201908678XA
SG11201908678XASG11201908678XASG11201908678XASG 11201908678X ASG11201908678X ASG 11201908678XASG 11201908678X ASG11201908678X ASG 11201908678XASG 11201908678X ASG11201908678X ASG 11201908678XA
Authority
SG
Singapore
Prior art keywords
international
antibody
pct
san diego
methods
Prior art date
Application number
Inventor
Jeffrey Johnson
Lawrence Dearth
Haralambos Hadjivassiliou
Jeonghoon Sun
Kandasamy Hariharan
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=62002401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201908678X(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene CorpfiledCriticalCelgene Corp
Publication of SG11201908678XApublicationCriticalpatent/SG11201908678XA/en

Links

Classifications

Landscapes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT ill Hu onus °nolo Hull oil onoinio oimIE (10) International Publication Number WO 2018/183182 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/US2018/024316 (22) International Filing Date: 26 March 2018 (26.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/477,257 27 March 2017 (27.03.2017) US (71) Applicant: CELGENE CORPORATION [US/US]; 86 Morris Avenue, Summit, NJ 07901 (US). (72) Inventors: JOHNSON, Jeffrey, C.; 5402 Foxtail Loop, Carlllsbad, CA 92010 (US). DEARTH, Lawrence; 602 Shanas Lane, Encinitas, CA 92024 (US). HADJI- VASSILIOU, Haralambos; 12791 Calle De La Siena, San Diego, CA 92130 (US). SUN, Jeonghoon; 4992 35th Street, San Diego, CA 92116 (US). HARIHARAN, Kandasamy; 6575 Little Mcgonigle Ranch Road, San Diego, CA 92130 (US). (74) Agent: GEORGE, Nikolaos, C. et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 1-1 KM, ML, MR, NE, SN, TD, TG). Published: co with international search report (Art. 21(3)) 00 1-1 (54) Title: METHODS AND COMPOSITIONS FOR REDUCTION OF IMMUNOGENICITY \" (57) : Provided herein are methods and uses involving the combination of an anti-CD20 antibody, e.g., rituximab with a protein 0 therapeutic, for example, an antibody (e.g., an antibody that specifically binds to human CD47).
SG11201908678X2017-03-272018-03-26Methods and compositions for reduction of immunogenicitySG11201908678XA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US201762477257P2017-03-272017-03-27
PCT/US2018/024316WO2018183182A1 (en)2017-03-272018-03-26Methods and compositions for reduction of immunogenicity

Publications (1)

Publication NumberPublication Date
SG11201908678XAtrue SG11201908678XA (en)2019-10-30

Family

ID=62002401

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11201908678XSG11201908678XA (en)2017-03-272018-03-26Methods and compositions for reduction of immunogenicity

Country Status (15)

CountryLink
US (2)US20200330590A1 (en)
EP (1)EP3601351A1 (en)
JP (2)JP7237848B2 (en)
KR (1)KR20190133198A (en)
CN (1)CN110612309A (en)
AU (1)AU2018244276A1 (en)
BR (1)BR112019020185A2 (en)
CA (1)CA3057841A1 (en)
CL (1)CL2019002716A1 (en)
CO (1)CO2019011640A2 (en)
EA (1)EA201992278A1 (en)
IL (1)IL269590A (en)
MX (1)MX2019011624A (en)
SG (1)SG11201908678XA (en)
WO (1)WO2018183182A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US11142584B2 (en)2014-03-112021-10-12Molecular Templates, Inc.CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
KR20170110601A (en)2015-02-052017-10-11몰레큘러 템플레이츠, 인코퍼레이션. Multivalent CD20 binding molecules comprising a < RTI ID = 0.0 > cigarotoxin A < / RTI >
IL268443B2 (en)2018-04-172024-07-01Molecular Templates IncHer2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
TW202104260A (en)*2019-04-052021-02-01美商西建公司Engineering of an antibody for tumor-selective binding of cd47
CN114206912B (en)2019-06-072025-02-11Alx肿瘤生物技术公司 Methods and reagents for reducing interference from drugs that bind CD47 in serological assays
CN114599392A (en)*2019-10-312022-06-07四十七公司anti-CD 47 and anti-CD 20 based treatment of leukemia
AU2021205144A1 (en)*2020-01-092022-08-25Innovent Biologics (Suzhou) Co., Ltd.Application of combination of anti-CD47 antibody and anti-CD20 antibody in preparation of drugs for preventing or treating tumors
EP4225793A1 (en)2020-10-072023-08-16Celgene CorporationBispecific antibody treatment of lymphoid malignant neoplasm conditions
US20220196651A1 (en)2020-12-062022-06-23ALX Oncology Inc.Multimers for reducing the interference of drugs that bind cd47 in serological assays

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB8308235D0 (en)1983-03-251983-05-05Celltech LtdPolypeptides
US4816567A (en)1983-04-081989-03-28Genentech, Inc.Recombinant immunoglobin preparations
US5807715A (en)1984-08-271998-09-15The Board Of Trustees Of The Leland Stanford Junior UniversityMethods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en)1986-03-271993-07-06Medical Research CouncilRecombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)1986-03-271986-04-30Winter G PRecombinant dna product
US5869620A (en)1986-09-021999-02-09Enzon, Inc.Multivalent antigen-binding proteins
US5530101A (en)1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
GB8928874D0 (en)1989-12-211990-02-28Celltech LtdHumanised antibodies
US5585112A (en)1989-12-221996-12-17Imarx Pharmaceutical Corp.Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (en)1990-04-171994-11-18Eurand Int METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
US5543390A (en)1990-11-011996-08-06State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences UniversityCovalent microparticle-drug conjugates for biological targeting
DE69233482T2 (en)1991-05-172006-01-12Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
WO1992022653A1 (en)1991-06-141992-12-23Genentech, Inc.Method for making humanized antibodies
AU2238292A (en)1991-06-141993-01-12Xoma CorporationMicrobially-produced antibody fragments and their conjugates
US5637481A (en)1993-02-011997-06-10Bristol-Myers Squibb CompanyExpression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
IE922437A1 (en)1991-07-251993-01-27Idec Pharma CorpRecombinant antibodies for human therapy
US5565332A (en)1991-09-231996-10-15Medical Research CouncilProduction of chimeric antibodies - a combinatorial approach
CA2507749C (en)1991-12-132010-08-24Xoma CorporationMethods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en)1992-02-191992-04-08Scotgen LtdAntibodies with germ-line variable regions
EP0656946B2 (en)1992-08-212010-03-31Vrije Universiteit BrusselImmunoglobulins devoid of light chains
US6005079A (en)1992-08-211999-12-21Vrije Universiteit BrusselsImmunoglobulins devoid of light chains
US5639641A (en)1992-09-091997-06-17Immunogen Inc.Resurfacing of rodent antibodies
DK0672142T3 (en)1992-12-042001-06-18Medical Res Council Multivalent and multi-specific binding proteins as well as their preparation and use
US6274552B1 (en)1993-03-182001-08-14Cytimmune Sciences, Inc.Composition and method for delivery of biologically-active factors
US5523092A (en)1993-04-141996-06-04Emory UniversityDevice for local drug delivery and methods for using the same
US5985307A (en)1993-04-141999-11-16Emory UniversityDevice and method for non-occlusive localized drug delivery
DE69427974T2 (en)1993-04-292001-12-06Unilever N.V., Rotterdam PRODUCTION OF ANTIBODIES OR FUNCTIONAL PARTS THEREOF, DERIVED FROM HEAVY CHAINS OF IMMUNOGLOBULINES FROM CAMELIDAE
US6004534A (en)1993-07-231999-12-21Massachusetts Institute Of TechnologyTargeted polymerized liposomes for improved drug delivery
US5759542A (en)1994-08-051998-06-02New England Deaconess Hospital CorporationCompositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en)1994-11-281997-08-26Haynes; Duncan HDrug releasing surgical implant or dressing material
US5731168A (en)1995-03-011998-03-24Genentech, Inc.Method for making heteromultimeric polypeptides
US6316652B1 (en)1995-06-062001-11-13Kosta SteliouDrug mitochondrial targeting agents
BR9606706A (en)1995-10-161999-04-06Unilever Nv Bispecific or bivalent antibody fragment analog use process to produce the same
US6039975A (en)1995-10-172000-03-21Hoffman-La Roche Inc.Colon targeted delivery system
TW345603B (en)1996-05-291998-11-21Gmundner Fertigteile GmbhA noise control device for tracks
CA2266629C (en)1996-10-012002-04-16Cima Labs Inc.Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en)1998-06-302000-10-17Aradigm CorporationTemperature controlling device for aerosol drug delivery
US6120751A (en)1997-03-212000-09-19Imarx Pharmaceutical Corp.Charged lipids and uses for the same
US6060082A (en)1997-04-182000-05-09Massachusetts Institute Of TechnologyPolymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US7951917B1 (en)1997-05-022011-05-31Genentech, Inc.Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en)1997-05-022002-05-23Genentech, Inc.Method for making multispecific antibodies having heteromultimeric and common components
US6048736A (en)1998-04-292000-04-11Kosak; Kenneth M.Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en)1999-04-142001-08-07Musc Foundation For Research DevelopmentTissue-specific and pathogen-specific toxic agents and ribozymes
DE60042789D1 (en)1999-11-292009-10-01Bac Ip B V IMMOBILIZED ANTIGEN-BINDING MOLECULES FROM A DOMAIN
IL166244A0 (en)2001-07-122006-01-15Jefferson FooteSuper humanized antibodies
US20050042664A1 (en)2003-08-222005-02-24Medimmune, Inc.Humanization of antibodies
US8227577B2 (en)2007-12-212012-07-24Hoffman-La Roche Inc.Bivalent, bispecific antibodies
EP2111869A1 (en)*2008-04-232009-10-28Stichting Sanquin BloedvoorzieningCompositions and methods to enhance the immune system
KR20120027055A (en)2009-06-262012-03-20리제네론 파라마큐티칼스 인코포레이티드Readily isolated bispecific antibodies with native immunoglobulin format
US20140140989A1 (en)*2012-02-062014-05-22Inhibrx LlcNon-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
CN104583235B (en)2012-06-082019-03-01苏特罗生物制药公司The antibody of the Unnatural amino acid residues containing site-specific, its preparation and application
HUE045227T2 (en)2012-08-312019-12-30Sutro Biopharma Inc Modified amino acids containing an azido group
CA2894439A1 (en)*2012-12-122014-06-19Vasculox Inc.Therapeutic cd47 antibodies
EP4137518A1 (en)*2013-02-062023-02-22Inhibrx, Inc.Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
US20170002060A1 (en)*2014-01-082017-01-05Moderna Therapeutics, Inc.Polynucleotides for the in vivo production of antibodies
US10870699B2 (en)2014-12-302020-12-22Celgene CorporationAnti-CD47 antibodies and uses thereof
JP2018535692A (en)*2015-09-212018-12-06エラスムス ユニバーシティ メディカル センターErasmus University Medical Center Anti-CD47 antibody and method of use

Also Published As

Publication numberPublication date
CN110612309A (en)2019-12-24
JP7237848B2 (en)2023-03-13
US20240075133A1 (en)2024-03-07
CL2019002716A1 (en)2020-05-29
EP3601351A1 (en)2020-02-05
IL269590A (en)2019-11-28
JP2020515577A (en)2020-05-28
WO2018183182A8 (en)2019-11-14
CO2019011640A2 (en)2020-02-18
WO2018183182A1 (en)2018-10-04
BR112019020185A2 (en)2020-06-02
MX2019011624A (en)2019-12-05
JP2023052145A (en)2023-04-11
AU2018244276A1 (en)2019-10-17
EA201992278A1 (en)2020-03-03
CA3057841A1 (en)2018-10-04
KR20190133198A (en)2019-12-02
US20200330590A1 (en)2020-10-22

Similar Documents

PublicationPublication DateTitle
SG11201908678XA (en)Methods and compositions for reduction of immunogenicity
SG11201807401RA (en)Therapeutic membrane vesicles
SG11201806496SA (en)Antigen binding proteins that bind pd-l1
SG11201903830TA (en)Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201903359RA (en)Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201903857UA (en)Antibodies to pd-1 and uses thereof
SG11201907867TA (en)Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201907855QA (en)Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201805709RA (en)Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201811640SA (en)Multispecific antigen binding proteins and methods of use thereof
SG11201901126UA (en)Combination therapy for cancer
SG11201804915RA (en)Methods for treating huntington's disease
SG11201809751XA (en)Egfr inhibitor compounds
SG11201809374VA (en)Cd40l-fc fusion polypeptides and methods of use thereof
SG11201907948TA (en)Formulations comprising pd-1 binding proteins and methods of making thereof
SG11201910134SA (en)Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201810927QA (en)Pd-l1-specific antibodies and methods of using the same
SG11201907253VA (en)Proteins binding bcma, nkg2d and cd16
SG11201907638QA (en)Proteins binding cd33, nkg2d and cd16
SG11201803703UA (en)Anti-complement factor c1q fab fragments and uses thereof
SG11201908056QA (en)Anti-par2 antibodies and uses thereof
SG11201906386XA (en)Combination therapy involving diaryl macrocyclic compounds
SG11201809793UA (en)Tl1a antibodies and uses thereof
SG11201810420YA (en)Antibodies to alpha-synuclein and uses thereof
SG11201807720TA (en)Methods and systems for determining antibiotic susceptibility

[8]ページ先頭

©2009-2025 Movatter.jp